The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.

Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer. 

Toxicity casts a shadow over vorasidenib’s prospects as possibly the first targeted therapy for low-grade glioma.